Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 23/2/2018
SIETES contiene 92199 citas

 
 
<< anterior 21 a 40 de 845 siguiente >>
Presentar resultados
Seleccionar todas
21.Tiene citas relacionadas Cita con resumen
Socías ME, Wood E. Epidemic of deaths from fentanyl overdose. BMJ 2017;359:j4355. [Ref.ID 102107]
22.Tiene citas relacionadas Cita con resumen
Makary MA, Overton HN, Wang P. Overprescribing is major contributor to opioid crisis. BMJ 2017;359:j4792. [Ref.ID 102106]
23.Tiene citas relacionadas Cita con resumen
O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden M. Deaths involving fentanyl, fentanyl analogs, and U-47700 — 10 states, July–December 2016. Morbidity and Mortality Weekly Report 2017;66:1-5. [Ref.ID 102103]
24. Cita con resumen
Casassus B. Contraception implant removed from global market. Lancet 2017;390:1576. [Ref.ID 102079]
25. Cita con resumen
Schuchat A, Houry D, Guy Jr GP. New data on opioid use and prescribing in the United States. JAMA 2017;318:425-6. [Ref.ID 102055]
26.Enlace a cita original Cita con resumen
Prasad V, Mailan S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med 2017;177:1569-75. [Ref.ID 102051]
28. Cita con resumen
Anónimo. Gilead agrees to acquire Kite Pharma in $11.9 billion deal. DIA Daily 2017:1. [Ref.ID 102034]
29. Cita con resumen
Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 National survey on drug use and health. Ann Intern Med 2017;167:293-301. [Ref.ID 102021]
30. Cita con resumen
Iacobucci G. NHS to stop funding homeopathy and some drugs in targeted savings drive. BMJ 2017;358:j3560. [Ref.ID 102013]
32. Cita con resumen
Jobski K, Schmedt N, Kollhorst B, Krappweis J, Schink T, Garbe E. Characteristics and drug use patterns of older antidepressant initiators in Germany. Eur J Clin Pharmacol 2017;73:105-13. [Ref.ID 101939]
33. Cita con resumen
Anónimo. PhRMA, BIO increased spending on federal lobbying. DIA Daily 2017:1. [Ref.ID 101918]
34. Cita con resumen
Anónimo. Se recomienda no iniciar nuevos tratamientos con ?Monoferro® (hierro-isomaltósido) debido al riesgo de reacciones graves de hipersensibilidad. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:1-2. [Ref.ID 101915]
35. Cita con resumen
Anónimo. More doctors disclose payments from drug companies . BMJ 2017;358:30 de junio. [Ref.ID 101667]
36. Cita con resumen
Guy Jr GP, Zhang K, Bohm MK, Lewis B, Young R, Murphy LB, Dowell D. Vital Signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66:697-704. [Ref.ID 101665]
37. Cita con resumen
Poudel DR, Acharya P, Ghimire S, Dhital R, Bharati R. Burden of hospitalizations related to adverse drug events in the USA: a retrospective analysis from large inpatient database. Pharmacoepidemiol Drug Saf 2017;26:635-41. [Ref.ID 101626]
38. Cita con resumen
Becker WC, Fiellin DA. Abuse-deterrent opioid formulations - Putting the potential benefits into perspective. N Engl J Med 2017;376:2103-5. [Ref.ID 101625]
39. Cita con resumen
Tanimoto T, Tsuda K, Kurokawa T, Mori J, Shimmura H. Essential medicines for universal health coverage. Lancet 2017;389:1880-1. [Ref.ID 101601]
40. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
Seleccionar todas
 
<< anterior 21 a 40 de 845 siguiente >>